Key result
Orgaran inhibits thrombosis longer and causes less bleeding than heparin in experimental models.
Why the study?
The pharmacological profile and risk/benefit ratio of Orgaran compared to heparin and low-molecular-weight heparins in experimental models were characterized.
Does Orgaran have a better pharmacological and safety profile compared to heparin in experimental models?
Does Orgaran have a better pharmacological and safety profile compared to heparin in experimental models?
Preclinical data suggest Orgaran offers a superior risk/benefit profile compared to heparin, providing effective antithrombotic activity with reduced bleeding risk.
No takes yet. Share an insight, caveat, or question.
Higher anti-Xa/anti-IIa profile of Orgaran characterized; leaves open comparative efficacy and safety versus heparinoids in clinical use.
D.G. Meuleman (2009) conducted a review in Thrombosis (experimental models). Orgaran (Org 10172) vs. Heparin was evaluated. In experimental models, Orgaran inhibited thrombosis with a longer duration of action and less bleeding-enhancing activity than heparin, suggesting a significantly better risk/benefit ratio.